MC38-hCD47/hPD-L1
Strain Information
表現型データ
Figure 1. hCD47/hPDL1 expression in wild-type MC38 and MC38-hCD47/hPDL1 cell lines.
Figure 2. Tumor growth curve of MC38-hCD47/hPDL1 syngeneic model (n=4).
Figure 3. The expression of hCD47/hPDL1 in humanized modified tumors by FACS.
Figure 4. Antitumor activity of Bispecific-antibody in two different treatment group (n=6).
関連の系統
あなたも好きかも
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
詳細At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
詳細